Description
TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody
indicated for:
Esophageal Cancer
• in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1).
• as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.
Gastric Cancer
• in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2- negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1).
Additional information
| Brand | TEVIMBRA® |
|---|---|
| Generic name | Tislelizumab injection |
| Form | Parenteral |
| Strength | 100mg/10mL |
| Manufacturer | BeOne |
| Documents | Either PO or prescription |
| Storage | Store in a refrigerator at 2 – 8°C. |
Reviews
There are no reviews yet.